Cancer Cause and Prevention Research in Indiana
Cancer Cause and Prevention Research (93.393) awarded $24.0 million to recipients in Indiana in 18 grants from fiscal 2021 to 2025, 0.7% of the program's national total. Trustees of Indiana University received the most, $16.1 million.
- Awarded in Indiana$24.0 million
- Awards18
- Share of the program0.7%
- Rank among states28th of 48
- National total$3.6 billion
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 10 | $3.3 million |
| FY 2022 | 12 | $4.5 million |
| FY 2023 | 11 | $5.4 million |
| FY 2024 | 11 | $5.8 million |
| FY 2025 | 9 | $5.0 million |
Recipients in Indiana
| Recipient | Type | Awards | Amount |
|---|---|---|---|
| Trustees of Indiana University | Colleges and universities | 8 | $16.1 million |
| Kovina Therapeutics Inc | Small businesses | 2 | $2.3 million |
| Trustees of Indiana University | Colleges and universities | 2 | $2.3 million |
| University of Notre Dame Du Lac | Colleges and universities | 2 | $2.1 million |
| Purdue University | Colleges and universities | 4 | $1.1 million |
Open opportunities under this program
- Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
- Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
- Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)
- Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
- National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
- HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
- Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
See all 60 on the program page
Questions people ask
How much Cancer Cause and Prevention Research money goes to Indiana?
$24.0 million from fiscal 2021 to 2025, across 18 awards. Indiana ranks 28th of 48 states and territories for this program.
Who receives Cancer Cause and Prevention Research money in Indiana?
The largest recipient is Trustees of Indiana University, with $16.1 million in 8 awards. Next are Kovina Therapeutics Inc and Trustees of Indiana University.
Can organizations in Indiana apply now?
Yes, 60 opportunities under this program are open or forecast on Grants.gov. Federal grants are national, so eligibility depends on the notice, not the state.
Cancer Cause and Prevention Research in other states
Other large programs in Indiana
- Grants to States for Medicaid
- Highway Planning and Construction
- Education Stabilization Fund
- National School Lunch Program
- Child Care and Development Block Grant
- Special Education Grants to States
- Children's Health Insurance Program
- Title I Grants to Local Educational Agencies
- Temporary Assistance for Needy Families
- Broadband Equity, Access, and Deployment Program